171 related articles for article (PubMed ID: 12045459)
1. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
Briasoulis E; Karavasilis V; Tzamakou E; Haidou C; Piperidou C; Pavlidis N
Anticancer Drugs; 2002 Jun; 13(5):481-9. PubMed ID: 12045459
[TBL] [Abstract][Full Text] [Related]
2. Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
Meerum Terwogt J; van Tellingen O; Nannan Panday VR; Huizing MT; Schellens JH; ten Bokkel Huinink WW; Boschma MU; Giaccone G; Veenhof CH; Beijnen JH
Anticancer Drugs; 2000 Oct; 11(9):687-94. PubMed ID: 11129729
[TBL] [Abstract][Full Text] [Related]
3. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
Sparreboom A; Verweij J; van der Burg ME; Loos WJ; Brouwer E; Viganò L; Locatelli A; de Vos AI; Nooter K; Stoter G; Gianni L
Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
[TBL] [Abstract][Full Text] [Related]
4. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
5. Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL).
De Giorgi U; Rosti G; Monti M; Frassineti GL; Marangolo M
Ann Oncol; 2003 Oct; 14(10):1588-9. PubMed ID: 14504063
[No Abstract] [Full Text] [Related]
6. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
7. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
[TBL] [Abstract][Full Text] [Related]
8. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.
Rischin D; Webster LK; Millward MJ; Linahan BM; Toner GC; Woollett AM; Morton CG; Bishop JF
J Natl Cancer Inst; 1996 Sep; 88(18):1297-301. PubMed ID: 8797769
[TBL] [Abstract][Full Text] [Related]
9. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of cremophor EL with bolus doxorubicin.
Millward MJ; Webster LK; Rischin D; Stokes KH; Toner GC; Bishop JF; Olver IN; Linahan BM; Linsenmeyer ME; Woodcock DM
Clin Cancer Res; 1998 Oct; 4(10):2321-9. PubMed ID: 9796961
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of weekly paclitaxel in advanced lung cancer.
Akerley W; Glantz M; Choy H; Rege V; Sambandam S; Joseph P; Yee L; Rodrigues B; Wingate P; Leone L
J Clin Oncol; 1998 Jan; 16(1):153-8. PubMed ID: 9440737
[TBL] [Abstract][Full Text] [Related]
12. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
[TBL] [Abstract][Full Text] [Related]
13. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration.
Briasoulis E; Karavasilis V; Anastasopoulos D; Tzamakou E; Fountzilas G; Rammou D; Kostadima V; Pavlidis N
Ann Oncol; 1999 Jun; 10(6):701-6. PubMed ID: 10442193
[TBL] [Abstract][Full Text] [Related]
14. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
Scripture CD; Szebeni J; Loos WJ; Figg WD; Sparreboom A
Cancer Biol Ther; 2005 May; 4(5):555-60. PubMed ID: 15917657
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
Gelderblom H; Mross K; ten Tije AJ; Behringer D; Mielke S; van Zomeren DM; Verweij J; Sparreboom A
J Clin Oncol; 2002 Jan; 20(2):574-81. PubMed ID: 11786588
[TBL] [Abstract][Full Text] [Related]
17. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study.
Hayashi RJ; Blaney S; Sullivan J; Weitman S; Vietti T; Bernstein ML;
J Pediatr Hematol Oncol; 2003 Jul; 25(7):539-42. PubMed ID: 12847320
[TBL] [Abstract][Full Text] [Related]
19. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]